Analysis Shows No Singulair, Suicide Link
Study Suggests Early Improvement in Emotional Well-Being
WebMD News Archive
Drugmaker: Findings No Surprise
Merck spokesman Ian McConnell says the finding comes as no surprise.
"This independent study adds further support to the large body of
evidence for the safety of Singulair," he tells WebMD.
Late in March, after the FDA investigation was announced, Merck senior
director of clinical research George Philip, MD, told WebMD that there were no
reports of suicides in 40 clinical studies involving 11,000 patients who took
Singulair belongs to a class of drugs called leukotriene receptor antagonists. The FDA
is reviewing post-marketing data on other drugs in the class to determine if
further investigation is warranted.
Two of the nation's largest asthma organizations also weighed in on the
Singulair-suicide issue after the FDA investigation was announced.
"There are no data from well-designed studies to indicate a link between
Singulair and suicide," officials with the American College of Allergy,
Asthma and Immunology and the American Academy of Allergy, Asthma and
Immunology noted in a joint statement.
"The concern expressed by the FDA is based entirely on case reports and
there is no indication that such effects apply to other leukotriene-modifying
The ACAAI and AAAAI statement further noted that, "based on the
information currently available, patients taking Singulair should continue to
take the medication as prescribed provided 1): the patient and physician feel
the medication is effective; and 2) the patient does not experience any
suicidal behavior or thoughts."